https://www.selleckchem.com/pr....oducts/afuresertib-g
Both showed highest OVA encapsulation at 67% and 73%, and sustained OVA release in SIF (96 hrs) at 65% and 64% respectively. BET results showed that nanopores were not blocked during surface modification. CD and SDS-PAGE showed that OVA conformational structure did not change after release from nanoparticles. Glycopyrronium bromide, a synthetic anticholinergic agent used to treat patients with chronic obstructive pulmonary disease (COPD), is eliminated from the body by renal excretion and therefore systemic exposure is ex
Like
Comment
Share
